Anti PD 1 sustained release therapeutic - UroGen Pharma
Latest Information Update: 29 Mar 2021
At a glance
- Originator UroGen Pharma
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 15 Mar 2021 Anti PD 1 sustained release therapeutic - UroGen Pharma is available for licensing as of 15 Mar 2021. https://www.urogen.com/our-pipeline-and-partners/
- 15 Mar 2021 UroGen Pharma enters into a research agreement with the Johns Hopkins University to study checkpoint inhibitors in glioblastoma multiformein
- 15 Mar 2021 Early research in Glioblastoma in USA (unspecified route)